Best Treatment for Meningioma
Gross total surgical resection remains the gold standard treatment for symptomatic meningiomas when safely achievable, with stereotactic radiosurgery (SRS) serving as an effective alternative for surgically inaccessible tumors or as primary treatment for small lesions.
Treatment Algorithm by Clinical Scenario
For Newly Diagnosed Symptomatic Meningiomas
Surgery is the primary treatment when the tumor can be completely removed without causing significant neurological harm 1. The goal is gross total resection including the involved dura, which offers the best chance for cure and lowest recurrence rates 2.
However, complete removal is often challenging when:
- Tumors involve critical neurovascular structures
- Tumors are located at the skull base
- Complete resection would cause unacceptable morbidity
In these situations, stereotactic radiosurgery becomes the preferred option rather than attempting a high-risk subtotal resection 1.
For Small, Asymptomatic Tumors
Observation is often the best strategy, particularly in elderly patients 2. Many meningiomas grow slowly or remain stable, and the risks of intervention may outweigh benefits.
Stereotactic Radiosurgery as Primary Treatment
SRS is recommended as an effective evidence-based treatment option (Level II recommendation) for WHO Grade I meningiomas 1. The International Stereotactic Radiosurgery Society guidelines demonstrate:
- 10-year local control rates: 71-100%
- 10-year progression-free survival: 55-97%
- Typical prescription dose: 12-15 Gy in a single fraction
- Generally low toxicity rates
SRS should be considered as primary treatment for:
- Small tumors in surgically difficult locations
- Skull base meningiomas where surgery carries high risk
- Patients who are medically inoperable
- Patient preference after informed discussion
Treatment by WHO Grade
WHO Grade 1 (Benign):
- Surgery if symptomatic and safely resectable
- SRS for small tumors or surgically challenging locations
- Observation for asymptomatic tumors in elderly patients
- Post-operative surveillance with MRI every 6-12 months 3
WHO Grade 2 (Atypical) and Grade 3 (Anaplastic):
- More aggressive surgical approach when feasible
- Adjuvant radiotherapy often necessary
- More frequent surveillance imaging required 3
- Consider emerging targeted therapies in clinical trial settings 4, 5, 6
Radiation Therapy Options
Beyond single-fraction SRS, other radiation modalities include:
- Fractionated stereotactic radiotherapy (SRT): Delivered over 5-6 weeks at 1.8-3.0 Gy per fraction 1
- Hypofractionated stereotactic radiotherapy (HSRT): Up to 5 fractions at ≥5 Gy per fraction 1
These are used for larger tumors where single-fraction SRS would pose excessive risk to adjacent structures.
Adjuvant Treatment After Subtotal Resection
When complete resection is not achieved, radiotherapy (SRS or fractionated) should be strongly considered to improve local control, particularly for higher-grade tumors 1.
Emerging Therapies for Recurrent/Refractory Disease
For tumors that fail surgery and radiation, emerging options include 4, 5, 6:
- Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor targeting
- Targeted agents: mTOR inhibitors (everolimus), anti-angiogenic agents (bevacizumab)
- Immunotherapy: PD-1/PD-L1 checkpoint inhibitors
- Molecular-targeted therapy based on specific mutations (AKT1, SMO, PIK3CA, TRAF7)
These remain largely experimental but show promise, particularly for aggressive subtypes.
Critical Pitfalls to Avoid
Do not attempt aggressive resection of skull base meningiomas when it will cause significant cranial nerve deficits or vascular injury—SRS offers excellent control with minimal morbidity 1.
Do not rely solely on histologic WHO grade for prognosis. Molecular profiling (TERT promoter mutations, CDKN2A/B deletions) provides superior prognostic information and should guide surveillance intensity 4, 7.
Do not use chemotherapy as standard treatment—it has shown limited benefit 2. Reserve systemic therapy for clinical trial settings or molecularly-targeted approaches in refractory cases.
Do not use CT for surveillance—MRI with and without contrast is the standard imaging modality for follow-up 3.
Surveillance Strategy
Post-treatment monitoring depends on WHO grade:
- Grade 1: MRI every 6-12 months, with molecular profiling helping optimize frequency 3
- Grades 2-3: More frequent imaging, especially monitoring for pseudoprogression and radiation necrosis 3
- DOTATATE PET/CT may be useful for WHO Grade 2-3 tumors to assess resection extent and response to radiotherapy 3